The effect and mechanism of aberrant 4E-BP1 expression in human esophageal squamous cell carcinoma
碩士 === 國立陽明大學 === 生化暨分子生物研究所 === 98 === Rapamycin is a potential anti-cancer drug in clinical trial phase III. By inhibiting mTOR activity, rapamycin blocks 4E-BP1 phosphorylation and consequently decreases the activity of eIF4E in translation, leading to cancer cells susceptible to the growth inhib...
| Main Authors: | , |
|---|---|
| Other Authors: | |
| Format: | Others |
| Language: | zh-TW |
| Published: |
2010
|
| Online Access: | http://ndltd.ncl.edu.tw/handle/06250437165400400490 |